TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: knee extensor CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PT‐0°
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RTi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physical fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: infection complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of severe exacerbations per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain associated with HyCoSy
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of HyCoSy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS values at 1 MAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS values at awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cannulation on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications (arterial puncture and haematoma)
Endpoint domain: Adverse events/effects
Primary endpoint: TIMI major/minor bleed
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-τ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained recovery during follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: average time to recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average time to recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertebral fusion cases at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative disc space height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer muscle spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved tolerance of activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: withdrawals for adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mucosal safety profiles
Endpoint domain: Adverse events/effects
Primary endpoint: mental health QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AFCL increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of intraabdominal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopmental stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Long-term adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Failure of repositioning of the Pavlik treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Maturation disorders of the hips
Endpoint domain: Adverse events/effects
Primary endpoint: Avascular necrosis of the femoral head
Endpoint domain: Adverse events/effects
Primary endpoint: subsidence of the Active stem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory loss measured by QST and QualST parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shame reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risky sexual behaviour reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder status at final evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tachycardia after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (HR) values after anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Arterial Pressure (MAP) values after anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 month patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: dry ear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: air-bone gap (ABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct ratio of CC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CC rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain VAS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent satisfaction with child's recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum alanine transaminase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reversal of fatty liver by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Peripheral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve desired level of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of care transition
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Questions about emotions associated with pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Questions about cognitions associated with pain treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Use of paternalistic statements about cancer pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression of kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: extracellular glutathione in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoroscopy exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Esophageal wall injury
Endpoint domain: Adverse events/effects
Primary endpoint: Wheal inhibition of at least 70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median duration of wheal inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total area under the curve for triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial incremental area under the curve for triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-hour Insulin Sensitivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: myofibrillar FSR responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: plasma CRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycogen storage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PTA rates achieving 40% T > MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFR against E. coli and Klebsiella spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal in-stent intimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological complaints improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perceived claudication pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of total quality-of-life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weight gain after HT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virological response 24 weeks post-treatment (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stably housed
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Perceived choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Combined incidence of CLD and/or death before discharge from hospital
Endpoint domain: Mortality/survival
Primary endpoint: Total high-order aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal and vertical decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident depression
Endpoint domain: Mortality/survival
Primary endpoint: Adjusted systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of pain associated with propofol injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteal E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Histologic evaluation of endometrial biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WMFT-Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of ischemic stroke, myocardial infarction, or other vascular death
Endpoint domain: Mortality/survival
Primary endpoint: overall incidence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical condition on the Clinician Global Impression Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of azithromycin-resistant S. aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Liver damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of platelet activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lung cancer development
Endpoint domain: Mortality/survival
Primary endpoint: Lung cancer-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sulcal Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of HF diagnosis and management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of small hepatic nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of virtual CT sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malignant potential of nodules 10 mm or smaller
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stable hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Higher cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced systemic and pulmonary vascular resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: I‐123 MIBG heart‐mediastinal tracer uptake ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HRV 5‐minute low‐frequency variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medicare reimbursement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: inpatient charges
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: utilization of home health care services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: successful outcome after hip and core strengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful outcome after knee strengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ARDS at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death, heart failure hospitalization, or aborted cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Posttreatment quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction in terms of snoring severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal inhibition of platelet thromboxane A2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative probabilities of success at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: mean enamel wear (in μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day incidence of major adverse cardiac events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum aluminum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily urinary aluminum excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent symptoms after 1 or 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone Mineral Density (BMD) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Migration of feeding tubes to postpyloric position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total pulmonary resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reading time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep difficulty
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence of grade 2 or 3 ARIE
Endpoint domain: Adverse events/effects
Primary endpoint: delay in ARIE onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in positive containers by house (C+/C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of satisfactory preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative ACD prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute prediction error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommendation for invasive testing based on nodule size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MMSE total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GRT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of children who were symptom-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PC20 (concentration of inhaled histamine causing a 20% fall in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nasal polyp scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum ADA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum CD26 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum DPP‐IV activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma estradiol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coefficients of variation of plasma estradiol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent of at-risk adolescents successfully screened
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability score
Endpoint domain: Adverse events/effects
Primary endpoint: Seropositivity to VZV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incisional pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitigation of tooth hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in DH after evaporative stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc prolongation with concomitant nefazodone and terfenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc prolongation with concomitant nefazodone and loratadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PBV decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mesenteric PI increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: coping adaptation process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WOMAC pain score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: body fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vascular cell adhesion molecule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Study withdrawal due to leucopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of bacterial infection
Endpoint domain: Adverse events/effects
Primary endpoint: oocyte recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Median NIHSS at discharge and follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Excellent clinical outcome (mRS 0-1) at last follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PBF perfusion units (PU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTH area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Alkaline phosphatase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone scan improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of early recurrence (ER)
Endpoint domain: Mortality/survival
Primary endpoint: more than 10 spontaneous respirations per minute within 8 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in steps/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOx level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBARs level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean off-therapy period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events due to hormonal deprivation
Endpoint domain: Adverse events/effects
Primary endpoint: Participation in the screening program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Follow-up BMI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains in nutrition knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peripheral blood saturation with oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes